Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AstraZeneca Pharma IndiaNSE:ASTRAZEN +0.37%93 Return-on-Tangible-Asset is 9.03% as of Mar. 2026, which is 15% below its 10-year median of 10.68. GuruFocus rates NSE:ASTRAZEN with a GF Score™ of 93/100 and a GF Value™ of ₹10,982.26 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,009 Drug Manufacturers companies, AstraZeneca Pharma India ranks better than 80.97% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. AstraZeneca Pharma India's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹1,795 Mil. AstraZeneca Pharma India's average total tangible assets for the quarter that ended in Mar. 2026 was ₹19,891 Mil. Therefore, AstraZeneca Pharma India's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 9.03%.
The historical rank and industry rank for AstraZeneca Pharma India's Return-on-Tangible-Asset or its related term are showing as below:
NSE:ASTRAZEN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.64 Med: 10.68 Max: 15.67
Current: 10.99
During the past 13 years, AstraZeneca Pharma India's highest Return-on-Tangible-Asset was 15.67%. The lowest was 4.64%. And the median was 10.68%.
NSE:ASTRAZEN's Return-on-Tangible-Asset is ranked better than 80.97% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs NSE:ASTRAZEN: 10.99
AstraZeneca Pharma India (NSE:ASTRAZEN) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
AstraZeneca Pharma India Return-on-Tangible-Asset Related Terms
AstraZeneca Pharma India Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for AstraZeneca Pharma India's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India Return-on-Tangible-Asset Chart
NSE:ASTRAZEN vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.03% mean?
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Return-on-Tangible-Asset of 9.03% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AstraZeneca Pharma India and its competitors. This is 15% below median its historical median of 10.68. Over the past decade, AstraZeneca Pharma India's Return-on-Tangible-Asset has ranged from 4.64 to 15.67. According to the industry distribution chart, AstraZeneca Pharma India ranks #192 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 19%.
Is AstraZeneca Pharma India's Return-on-Tangible-Asset too high?
AstraZeneca Pharma India's current Return-on-Tangible-Asset of 9.03% is 15% below median its 10-year median of 10.68. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 15.67. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. AstraZeneca Pharma India's value of 9.03% is 185.8% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #192 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #192 out of 1009 companies for Return-on-Tangible-Asset. This places AstraZeneca Pharma India in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. AstraZeneca Pharma India's value of 9.03% is 185.8% above this benchmark. Historically, AstraZeneca Pharma India's own Return-on-Tangible-Asset has ranged from 4.64 to 15.67 over the past decade. While the company's 10-year median is 10.68 vs. the industry median of 3.16, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Return-on-Tangible-Asset of 9.03% is 185.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Return-on-Tangible-Asset is 9.03%, which is 15% below median its own 10-year median of 10.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,982.26, compared to a current price of ₹8,228.50 — trading 25.1% below its estimated fair value. The current Return-on-Tangible-Asset is 9.03%, which is 15% below median its 10-year median of 10.68 and 185.8% above the Drug Manufacturers industry median of 3.16. AstraZeneca Pharma India's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Return-on-Tangible-Asset is 9.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,228.50 is trading 25.1% below its estimated GF Value™ of ₹10,982.26.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
Return-on-Tangible-Asset: 9.03% (15% below median its 10-year median of 10.68)
GF Value™: ₹10,982.26 vs. price of ₹8,228.50 (25.1% below fair value)
Industry Position: 185.8% above the Drug Manufacturers median (#192 of 1009)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
93GF Score
Get the complete analysis for NSE:ASTRAZEN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
